Significant Reduced Loss of Brain Volume in Multiple Sclerosis Patients Treated with Teva Pharmaceutical Industries Limited (TEVA)'s COPAXONE(R)  
10/11/2011 11:58:47 AM

JERUSALEM, Israel--(BUSINESS WIRE)--Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE® (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies (DMTs).